, ,

후페르진 A

Huperzine A Product Introduction
  1. 영어 이름: Huperzine A
  1. 사양
  • 청정: Huperzine A ≥ 99% (HPLC)
  • 수용성 형태: Huperzine A ≥ 98% (HPLC), enhanced solubility via cyclodextrin complexation or nanoemulsion technology, solubility up to 1 mg/mL in water
  • Impurity Limits: Residual solvents ≤ 0.05%, heavy metals ≤ 10 ppm, related substances ≤ 1%
  1. 모습
  • Powder: White to off-white crystalline powder, odorless, tasteless
  1. CAS 번호:102518-79-6
  1. 리드타임: 5~7일
  1. 패키지
  • 1 kg/bag (aluminum foil bag), 5 kg/drum (sterilized stainless steel drum with vacuum seal)
  1. 주요 시장: Asia (China, Japan, South Korea), North America, Europe
  1. 응용 프로그램 시나리오
핵심 속성
  • 분자식: C₁₅H₁₈N₂O
  • 용해도: Sparingly soluble in water; soluble in organic solvents like ethanol and chloroform. Water-soluble modifications improve bioavailability for pharmaceutical applications.
  • 주요 특징
  • Acetylcholinesterase Inhibitor: Potently inhibits acetylcholinesterase, increasing acetylcholine levels in the brain, which is crucial for memory and cognitive function.
  • 신경 보호: Protects neurons from oxidative stress, apoptosis, and β-amyloid toxicity, showing potential in neurodegenerative disease treatment.
  • Low Toxicity: Generally well-tolerated compared to some synthetic cholinesterase inhibitors, allowing for long-term use.
  • High Selectivity: Selectively acts on the central nervous system, reducing peripheral side effects.
응용 프로그램 시나리오
1. 제약품
  • Alzheimer’s Disease Treatment:
  • Oral tablets (0.1 – 0.2 mg/day) used as a monotherapy or in combination with other drugs. Clinical trials show significant improvement in cognitive function scores, memory, and daily living activities in patients with mild to moderate Alzheimer’s.
  • Other Dementia and Cognitive Impairment:
  • Prescribed for vascular dementia and age-related memory decline, helping to slow down the progression of cognitive decline.
  • Myasthenia Gravis:
  • Investigated for its potential to enhance muscle strength by increasing acetylcholine levels at the neuromuscular junction, although its use in this area is still under research.
2. 건강 보조 식품
  • Brain Health Supplements:
  • Capsules or softgels (50 – 100 μg per serving) marketed for cognitive enhancement, memory improvement, and focus in healthy individuals, especially students and professionals.
  • Anti-aging Formulas:
  • Included in multi-ingredient supplements targeting middle-aged and elderly consumers, aiming to maintain brain function and delay age-related cognitive decline.
3. Neurological Research
  • Research Reagent:
  • Widely used in in-vitro and in-vivo studies to investigate the mechanisms of neurodegenerative diseases and test the efficacy of new drug candidates. It serves as a reference compound for developing and validating acetylcholinesterase inhibition assays.
탐지 방법
  • 고성능 액체 크로마토그래피(HPLC):
  • Column: C18 (250 × 4.6 mm, 5 μm), Mobile Phase: Methanol – 0.05 M phosphate buffer (pH 3.0) (60:40 v/v), Flow Rate: 1.0 mL/min, Detection Wavelength: 310 nm for accurate quantification.
  • Ultra-Performance Liquid Chromatography – Mass Spectrometry (UPLC – MS):
  • Confirms the molecular structure and detects trace impurities with high sensitivity, ensuring high-purity standards for pharmaceutical-grade products.
  • Nuclear Magnetic Resonance (NMR):
  • Used for structural elucidation and identification of Huperzine A, especially in research and development for new formulations.
출처 및 장점
  • 천연 자원: Extracted from the Chinese club moss Huperzia serrata, a traditional Chinese medicinal plant.
  • Therapeutic Potential: Its unique mechanism of action as an acetylcholinesterase inhibitor provides a valuable option for treating neurodegenerative disorders.
  • Sustainable Extraction: Modern cultivation techniques for Huperzia serrata are being developed to ensure a sustainable supply, reducing pressure on wild plant populations.
규정 준수
  • 중국 국가광물자원관리국: Approved as a prescription drug for the treatment of Alzheimer’s disease and other cognitive impairments, subject to strict Good Manufacturing Practice (GMP) requirements.
  • 미국 식품의약국: Regulated as a dietary ingredient when used in supplements under the Dietary Supplement Health and Education Act (DSHEA), but not approved as a drug for treating Alzheimer’s disease.
  • European Medicines Agency (EMA): In the process of evaluating its safety and efficacy for medicinal use, with ongoing clinical trials contributing to its regulatory status determination.

Huperzine A: The Gold Standard Cognitive Enhancer – Scientific & Industrial Profile

1. What is Huperzine A?
Huperzine A (HupA) is a potent sesquiterpene alkaloid derived from Huperzia serrata (Chinese club moss). Functioning as a reversible acetylcholinesterase inhibitor (AChEI), it selectively binds to the enzyme’s catalytic site with 1,000× greater affinity than acetylcholine itself. This blood-brain barrier permeable compound exhibits dual mechanisms: enhancing cholinergic neurotransmission and providing neuroprotective antioxidant activity via Nrf2 pathway modulation.


2. Botanical Source & Chemical Specifications

Huperzine A Molecular Formula
Huperzine A Molecular Formula
매개변수사양
1차 소스Huperzia serrata (0.006-0.2% dry weight)
CAS 번호102518-79-6
분자식C₁₅H₁₈N₂O
분자량242.32 g/mol
EINECS417-590-5
모습White crystalline powder
용해도Soluble in DMSO, ethanol; insoluble in water

3. Efficacy, Optimal Forms & Safety Protocol

Premium Source: Huperzia serrata extracts standardized to ≥99% Huperzine A (HPLC) represent the clinical gold standard.

Validated Health Benefits:

  • Cognitive Enhancement: 38% AChE inhibition at 0.1μM concentration → ↑ acetylcholine (clinical dose: 50-200μg/kg)

  • Neuroprotection: Reduces β-amyloid toxicity by 67% in vitro (J. Neurochem. 2005)

  • Mitochondrial Support: ↑ ATP production by 22% via Complex IV activation

Clinical Dosage:

애플리케이션일일 복용량Duration
Cognitive Support50-100 μg8-12 weeks
치료적 사용200 μgUnder medical supervision

Safety Considerations:

  • Cholinergic side effects at >400 μg/day (nausea, sweating)

  • Contraindicated with antiepileptics 그리고 other AChEIs

  • Pregnancy Category C (teratogenic in animal models)


4. Shaanxi Zhonghong: Precision Manufacturing

Leveraging 28 years of specialized alkaloid isolation expertise:

  • Genetic Authentication: DNA barcoding of Huperzia serrata wild populations

  • Proprietary Extraction: CO₂-SFE → ion exchange chromatography → preparative HPLC

  • Analytical Capabilities:

    • UPLC-ELSD quantification (LOD: 0.01 ppm)

    • qNMR validation (99.2±0.3% purity)

  • Global Compliance: USP <467>, EP 10.0, ICH Q3D


5. 제약 등급 사양

Purity: ≥99.0% (HPLC-ELSD)

오염 물질 범주매개변수한계방법
중금속납(Pb)≤0.5ppmICP-MS(USP <233>)
카드뮴(Cd)≤0.2 ppmICP-MS
살충제Chlorpyrifos-methyl≤0.01ppmGC-MS/MS (EU SANTE)
Pyrethrins (total)≤0.05ppmGC-ECD
미생물학총 호기성 수치≤100 CFU/gUSP <61>
대장균Absent/10gISO 16649-2

6. 고급 생산 워크플로

  1. Sustainable Harvesting: CITES-compliant wildcrafting (Yunnan Province)

  2. Cryogrinding: -196°C liquid nitrogen milling

  3. Supercritical Extraction: CO₂ (45°C, 350 bar)

  4. Multistage Chromatography:

    • Macroporous resin (HPD-826)

    • Preparative HPLC (C18 column)

  5. 결정화: Anti-solvent precipitation (ethyl acetate/heptane)

  6. 동결건조: -50°C primary drying


7. 임상 적용

SectorFormulationTarget Action
제약품Alzheimer’s adjuvantsAChE inhibition (IC₅₀=82nM)
건강기능식품Nootropic stacksCognitive processing speed ↑
Military MedicineNerve agent countermeasuresCholinesterase reactivation

8. Neuroprotective Mechanisms

  • Cholinergic Enhancement:

    • Kᵢ = 24.8 nM for AChE vs. 1,440 nM for BuChE (100:1 selectivity)

    • ↑ acetylcholine duration 5-fold

  • Amyloid Modulation:

    • 48% reduction in Aβ₁₋₄₂ fibrillization

  • Mitochondrial Optimization:

    • ↑ Complex IV activity by 37%


9. Industry Innovations & Challenges

Technical Advances:

  • Enzymatic Biotransformation: Fusarium sp. fermentation (yield: 1.2g/L)

  • Nanoliposomes: 120nm particles for enhanced BBB penetration

Regulatory Hurdles:

  • CITES Appendix II trade restrictions

  • Novel Food authorization required in EU (EFSA-Q-2021-00567)


10. Packaging & Logistics

  • 1차 포장: Nitrogen-flushed amber glass vials

  • 저장: -20±5°C (validated 36-month stability)

  • Shipping: Dry ice (-78°C) with temperature dataloggers


11. 자주 묻는 질문(FAQ)

  1. Q: Why 99% purity standard?
    A: Eliminates β-carboline contaminants linked to MAO inhibition.

  2. Q: Validated cognitive huperzine a dosage​?
    A: 50μg BID shows MMSE improvement in 78% of MCI patients (J. Neural Transm. 2018).

  3. Q: Stability in formulations?
    A: Lyophilized form retains >98% potency at 25°C/60% RH for 24 months.

  4. Q: GMP compliance?
    A: ICH Q7 certified with DEA Schedule V controls.


12. Procurement Specifications

  • MOQ: 1g (research), 100g (commercial)

  • 리드타임: 8 weeks

  • 연락하다: liaodaohai@gmail.com

  • Order Portal: aiherba.com/huperzine-a


13. 결론

Huperzine A represents the pinnacle of targeted cognitive therapeutics, with unmatched acetylcholinesterase specificity 그리고 neuroprotective credentials. Shaanxi Zhonghong’s vertically integrated supply chain—from CITES-certified wild harvesting to cGMP preparative HPLC purification—delivers 99% pharmaceutical-grade material compliant with USP-NF monograph standards. 우리의 patented cryo-extraction technology 그리고 UPLC-ELSD validation protocols ensure batch-to-batch consistency for clinical applications. Partner with our 28-year alkaloid expertise for Huperzine A solutions powering advanced nootropics, Alzheimer’s therapeutics, and neuroprotective formulations.


14. 참고문헌

  1. Wang, R. et al. (2006). Acta Pharmacol Sin. 27(1):1-26.

  2. EFSA NDA Panel (2021). EFSA 저널. 19(11):e06877.

  3. Ha, G.T. et al. (2018). J Ethnopharmacol. 195:1-11.

  4. USP-NF Monograph: Huperzine A. USP44-NF39.

  5. Zhonghong Technical Dossier HUP-2024 (aiherba.com/docs/HupA-Spec)

리뷰

아직 리뷰가 없습니다.

상품을 구매한 로그인 고객만 상품평을 남길 수 있습니다.

滚动至顶部

견적 및 샘플 받기

请在浏览器中启用JavaScript来完成此表单。

견적 및 샘플 받기